Neoadjuvant Oncolytic Virus OrienX010 Combined with PD-1 Inhibitor Toripalimab for Resectable Acral Melanoma: Phase Ib Clinical Trial Background Acral melanoma (AM) is a highly aggressive subtype of melanoma with a high incidence in the Chinese population, accounting for approximately 40% of melanoma cases. Despite advances in melanoma treatment, c...